Just over 50% of patients with advanced rectal cancer have a poor response to chemoradiotherapy with resultant poor outcomes. Professor Glimelius reviews the evidence base for defining such patients and the potential role, if any, of further treatment.
What is a poor response to chemoradiotherapy?
First of all, what is a poor response to chemoradiotherapy (CRT)? In most cases a poor response is where there is no, or limited, tumour regression on MRI (with an unfavourable tumour regression grade, with predominant tumour cells, many nodes or EMVI) or no signs of pathological tumour response. In these cases it is feared that the outcome will be poor and we may wish to give more therapy. In selected cases, complete clinical remission (cCR) will be the aim (for example, where organ preservation is the desired outcome) and less than a cCR is then a poor response.
Multiple studies have shown that poor responders do worse and outcomes are best for those patients who achieve a pathological complete response [1] . Partial responders also do well although there are some split opinions regarding this. The question is how well or how badly do the poor responders do? This is a difficult question because, in all the reports, how well or how badly the poor responders do has rarely been reported.
Park et al. showed that poor responders have an increased risk of recurrence (about 40%) [2] (Fig. 1) and similar results were shown by Lim et al. [3] ; however, these results depend on the definitions of good prognosis and poor prognosis.
Thus, about 60% of patients who are 'poor responders' after CRT are cured [2, 3] . The question remains, what is the best management for the patients with poorly responding tumours?
Management of poor responders
First of all, it is crucial for these patients still undergo surgery because surgery cures many. Following surgery, the medical oncologist will be consulted, and there is also ongoing research by basic and translational tumour biologists, which may be influential in 3-5 years.
Do poor responders to CRT gain from adjuvant therapy?
It is very difficult to determine whether poor responders to CRT who have had surgery gain from adjuvant treatment. Whether adjuvant therapy has any effect in rectal cancer treatment is a very controversial question. Extrapolators say 'yes', whereas recent trials say 'no' [4] [5] [6] [7] [8] . Moreover, the meta-analyses of those trials also say no [9, 10] . So, all in all, there is no, or only limited, gain from giving adjuvant therapy in patients who have had neoadjuvant CRT.
Population-based and some hospital-based studies show that there is some gain but that this gain is subject to selection bias. Is there a gain in subgroups [4] , and above all, is there a gain in poor responders?
We only have retrospective studies to rely on. The study by Collette et al. is a classical retrospective study which concluded that poor responders have no gain from CRT and good responders (for whom adjuvant chemotherapy is not really indicated) did appear to have some gain [11] .
A further recent retrospective study comes from a trial in which the addition of oxaliplatin, given pre-and postoperatively, revealed an overall gain in disease-free survival with a hazard ratio of about 0.8 [12] . Subgroup analyses showed intriguing results. Patients with a good response (ypT0-1) showed no gain in diseasefree survival (and therefore no need for oxaliplatin). There was no meaningful improvement with further treatment intensification in patients with poor response (defined as N2) [12] . To the best of our knowledge, this is the only study in patients with rectal cancer which shows that poor response to CRT means resistance to further therapy, in this case further oxaliplatin. This has been reported in other tumours.
What predicts response to CRT?
Multiple studies over recent decades have attempted to identify biomarkers for treatment resistance, each of which reports on 30-100 patients with results showing mildly significant P values but with wide confidence intervals. Whilst there may be some scientific value, these biomarkers have no clinical value.
Conclusions
So, for poor responders to CRT on MRI, the fight should go on; surgery is important, but adjuvant chemotherapy is probably meaningless and new drugs against different targets need to be explored. Surgery as the sole modality can remove 1 kg of tumour cells, radiation about 1 g with high probability and the seven or eight drugs presently available might eradicate 1 mg of tumour per deposit, again with high probability.
So, to conclude, it is bad biology, but outcome is not all that bad if you operate and we need to find even better drugs. 
Summary of the key points
• There is a current lack of consensus to define a poor response to chemoradiotherapy.
• Outcomes for poor responders have rarely been reported.
• There is no, or only limited, gain of adjuvant therapy in patients who have had neoadjuvant chemoradiotherapy.
• There is lack of prospective trial evidence to show benefit of further treatment in poor responders.
• Biomarkers for prediction of response to chemoradiotherapy have no clinical value.
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